Known targets — ChEMBL curated mechanism
ABCC9ABL1ACEACHEACVR1ADORA1ADORA2AADORA2BADORA3ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALOX5ATP4AATP4BBCRBTKCACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGCRBNCUL4ACXCR1CXCR2DDB1DDCDHFRDPP4DRD2DRD3DRD4EGFRERBB2ERBB4ESR1ESR2FDPSFKBP1AFLT1FLT3FLT4GARTGHSRGRIA1GRIA2GRIA3GRIA4GRIK1GRIK2GRIK3GRIK4GRIK5GRIN2AGSK3AGSK3BHDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IDH1IDH2IMPA1ITGA2BITGB3JAK1JAK2JAK3KCNJ11KCNK3KCNK9KDRKITMEN1METMMP1MMP13MMP7MMP8NANOD2NS5bODC1OPG057OPRD1OPRK1OPRM1PPARP1PARP2PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDGFRBPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PKLRPPARDPPATPTGS1PTGS2RBX1ROCK1ROCK2RRM1RRM2RRM2BSCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC10A2SLC5A2SLC6A2SLC6A3SLC6A4SLC9A3SYKTACR1THRATHRBTOP1TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYK2TYMSVDRampCblablaT-3blaT-4blaT-5blaT-6blaUOE-1dacAdacBdacCfolAfolPftsIgyrAgyrBileSmecAmrcAmrcBmrdAparCparEpbp2pbp4pbpApbpFrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUthyAykgMykgO
The experimentally established mechanism targets of Pyrrolidine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A known ✓ | P27815 | 1/20 | 0.50 |
| ▸ | KDR known ✓ | P35968 | 1/20 | 0.50 |
| ▸ | MEN1 known ✓ | O00255 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.80 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.64 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.64 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pyrrolidine SCHEMBL28547040 | 1.00 | ALDH1A1 (0.80) | ALDH1A1CXCR4SMN1; SMN2HIF1AMAPT | |
| Pyrrolidine SCHEMBL724812 | 1.00 | — | — | |
| Pyrrolidine SCHEMBL3853339 | 1.00 | ALDH1A1 (0.80) | ALDH1A1CXCR4SMN1; SMN2HIF1AMAPT | |
| Pyrrolidine SCHEMBL29194307 | 0.95 | — | — | |
| Piperidine SCHEMBL7575329 | 0.95 | ALDH1A1 (0.90) | ALDH1A1CXCR4SMN1; SMN2HIF1AMAPT | |
| Piperidine SCHEMBL4616564 | 0.95 | — | — | |
| Pyrrolidine SCHEMBL28458206 | 0.95 | — | — | |
| Azepane SCHEMBL20563677 | 0.95 | — | — | |
| Piperidine SCHEMBL7575332 | 0.95 | — | — | |
| Piperidine SCHEMBL781392 | 0.95 | ALDH1A1 (0.90) | ALDH1A1CXCR4SMN1; SMN2HIF1AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250304588-A1 | PROCESS FOR PREPARING BETA 3 AGONISTS AND INTERMEDIATES | MERCK SHARP & DOHME LLC | 2025-10-02 | — | — | US | disclosed |
| US-12180219-B2 | Process for preparing beta 3 agonists and intermediates | MERCK SHARP & DOHME LLC (US) | 2024-12-31 | — | — | US | disclosed |
| US-20240300960-A1 | PROCESS FOR PREPARING BETA 3 AGONISTS AND INTERMEDIATES | MERCK SHARP & DOHME LLC | 2024-09-12 | — | — | US | disclosed |
| US-20240300955-A1 | PROCESS FOR PREPARING BETA 3 AGONISTS AND INTERMEDIATES | MERCK SHARP & DOHME LLC (US) | 2024-09-12 | — | — | US | disclosed |
| CN-116573968-A | Urea slow-release agent and preparation method thereof | 广西植保科技有限公司 | 2023-08-11 | — | — | CN | disclosed |
| CN-116573968-A | Urea slow-release agent and preparation method thereof | 广西植保科技有限公司 | 2023-08-11 | — | — | CN | disclosed |
| US-11649243-B2 | Process for preparing beta 3 agonists and intermediates | MERCK SHARP & DOHME CORP. (US) | 2023-05-16 | — | — | US | disclosed |
| US-20220073523-A1 | PROCESS FOR PREPARING BETA 3 AGONISTS AND INTERMEDIATES | MERCK SHARP & DOHME LLC | 2022-03-10 | — | — | US | disclosed |
| US-8580821-B2 | Serotonin transporter (SERT) inhibitors for the treatment of depression and anxiety | HOFFMANN-LA ROCHE INC. (US) | 2013-11-12 | — | — | US | disclosed |
| EP-2004605-B1 | PIPERIDINE DERIVATIVES USEFUL AS SEROTONIN TRANSPORTER INHIBITORS AND NEUROKININ-1 RECEPTOR ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2011-06-29 | — | — | EP | disclosed |
| EP-2004605-A1 | PIPERIDINE DERIVATIVES USEFUL AS SEROTONIN TRANSPORTER INHIBITORS AND NEUROKININ-1 RECEPTOR ANTAGONISTS | F. Hoffmann-Roche AG (CH) | 2008-12-24 | — | — | EP | disclosed |
| EP-1957450-A1 | SEROTONIN TRANSPORTER (SERT) INHIBITORS | F.HOFFMANN-LA ROCHE AG (CH) | 2008-08-20 | — | — | EP | disclosed |
| WO-2007113153-A1 | PIPERIDINE DERIVATIVES USEFUL AS SEROTONIN TRANSPORTER INHIBITORS AND NEUROKININ-1 RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2007-10-11 | — | — | WO | disclosed |
| US-20070232652-A1 | Serotonin transporter (sert) inhibitors for the treatment of depression and anxiety | HOFFMAN-LA ROCHE INC. | 2007-10-04 | — | — | US | disclosed |
| WO-2007063009-A1 | SEROTONIN TRANSPORTER (SERT) INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2007-06-07 | — | — | WO | disclosed |
| US-20070129419-A1 | Serotonin transporter (SERT) inhibitors for the treatment of depression and anxiety | HOFFMANN-LA ROCHE INC. | 2007-06-07 | — | — | US | disclosed |
| CN-1859914-A | Phenyl pyrrolidine ether tachykinin receptor antagonists | MERCK & CO INC (US) | 2006-11-08 | — | — | CN | disclosed |
| EP-1670476-A2 | PHENYL PYRROLIDINE ETHER TACHYKININ RECEPTOR ANTAGONISTS | Merck & Co., Inc. (US) | 2006-06-21 | — | — | EP | disclosed |
| WO-2005032464-A3 | PHENYL PYRROLIDINE ETHER TACHYKININ RECEPTOR ANTAGONISTS | MERCK & CO INC (US) | 2005-08-04 | — | — | WO | disclosed |
| WO-2005032464-A2 | PHENYL PYRROLIDINE ETHER TACHYKININ RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 2005-04-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11649243-B2 | Process for preparing beta 3 agonists and intermediates | ADRB3, ADRA1D, ADRB1 | PDE4A 413/4885KDR 1630/4885MEN1 2836/4885 |
| US-20250304588-A1 | PROCESS FOR PREPARING BETA 3 AGONISTS AND INTERMEDIATES | ADRB3, ADRA1D, ADRB1 | PDE4A 413/4885KDR 1630/4885MEN1 2836/4885 |
| US-20220073523-A1 | PROCESS FOR PREPARING BETA 3 AGONISTS AND INTERMEDIATES | ADRB3, ADRA1D, ADRB1 | PDE4A 413/4885KDR 1630/4885MEN1 2836/4885 |
| US-20070232652-A1 | Serotonin transporter (sert) inhibitors for the treatment of depression and anxiety | SLC6A4, SLC6A1, SLC1A2 | PDE4A 3260/4885KDR 488/4885MEN1 2614/4885 |
| US-20070129419-A1 | Serotonin transporter (SERT) inhibitors for the treatment of depression and anxiety | SLC6A4, SLC6A2, SLC6A3 | PDE4A 2487/4885KDR 2107/4885MEN1 1827/4885 |
| US-20240300960-A1 | PROCESS FOR PREPARING BETA 3 AGONISTS AND INTERMEDIATES | ADRB3, ADRA1D, ADRB1 | PDE4A 413/4885KDR 1630/4885MEN1 2836/4885 |
| US-12180219-B2 | Process for preparing beta 3 agonists and intermediates | ADRB3, ADRA1D, ADRB1 | PDE4A 413/4885KDR 1630/4885MEN1 2836/4885 |
| US-20240300955-A1 | PROCESS FOR PREPARING BETA 3 AGONISTS AND INTERMEDIATES | ADRB3, ADRA1D, ADRB1 | PDE4A 413/4885KDR 1630/4885MEN1 2836/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.